133 Times times Record P/E Watson biology shareholder share 7.1 billion fortune

21st Century Economic Report Xiao Qing Guangzhou reported the legend of the creation of the gem to continue.　　November 1, Watson's bio-issue of new shares, up to 133.8 times times the sky-high price-earnings ratio of the share market to record a new high, the final confirmation of its initial public offering a A shares of 95 yuan.　　Data show that Watson's biological distribution of 25 million shares, the number of fund-raising will be as high as 2.375 billion yuan. At the price of the price, Watson's 22 founders will be able to sit on the book wealth of 7.125 billion yuan.　　Among them, the Chairman and general manager Li Yuanchun to 1.429 billion yuan, two first sneaked into the venture company Hongta and Changan venture capital wealth also respectively up to 782 million yuan and 356 million yuan. In particular, a year before the listing of two mysterious natural persons Yiu Dingbong and Sumin can also sit on the "rocket" of wealth appreciation.　　Before the release, Yiu Dingbong and Sumin invested 6 million yuan and 1.5 million yuan respectively, holding 1.5 million shares and 375,000 shares, the corresponding book wealth of 142.5 million yuan and 35.625 million yuan, so as to enter the ranks of billionaires and tens of millions of millionaires. Collective-making spree for Watson, a sky-high IPO means the beginning of a collective-building spree. Public information shows that the company does not have actual control.　　Before the listing, the company has 22 shareholders, the first 3 major shareholders Li Yunchun, Liu Junhui, Yuxi Real estate holdings were 20.06%, 15.19%, 12.7%. Up to now, Li Yuanchun shareholding 15.0458 million shares, accounting for the company issued 15.05% of the total share capital, director Liu Junhui, directors, deputy general manager Chen Lijia and directors, deputy general Manager Liu Hongyan respectively holding 11.3906 million shares, 8.2315 million shares, 6.9662 million shares,　　The share of total equity after the company was issued was 11.39%, 8.23% and 6.97%, respectively. In addition, the company's second largest shareholder in Yuxi real estate 9.5273 million shares, accounting for the company after the issuance of the total share capital of 9.53%. The Watson Bio prospectus shows that Yuxi real estate invested 10 million yuan in the Watson bio-capital increase on November 30, 2004. If the 95 yuan per share of the price calculation, Yuxi real estate investment in the past 6 years brought by the book Wealth of up to 905 million yuan, capital return as high as 89.51 times times Yuxi Real estate was established on November 9, 1993, by 24 natural Persons Unit composition.　　As of June 30, 2010, Yuxi Real Estate in the first half of 2010 to achieve operating income of 40.1048 million yuan, net profit of 4.3279 million yuan. and the Hongta investment on March 31, 2008, with monetary capital of 24 million yuan to increase the company's capital of 1.6965 million yuan.　　Up to now, the HONGTA venture capital shareholding ratio for the company after the issuance of the total share capital of 7.5%; Shenzhen Changan Innovative Investment Partnership (limited partnership) with money capital of 12 million yuan to add 848200 yuan. However, due to the legal entity qualification of the limited partnershipThere is a certain controversy, in March 2009, Shenzhen Changan Innovative Investment Partnership (limited Partnership) will be held by the company's total stake in the original capital price transfer to Shenzhen Changan Innovative Investment Partnership (limited Partnership) General partner Kushangyun, Liu Zhifeng Holdings of Changan Venture capital (its time Kushangyun, Liu Zhifeng each holding 40%, Wang Nie shareholding 20%).　　Up to now, Changan Venture investment shareholding ratio is 3.75%.　　The most fortunate shareholder is Sumin, Yiu Dingbong, a two-person shareholder who shares a year ago. Watson said that in order to solve the needs of individual funds, after the listing of the company to focus on vaccine development and production, Chen Lijia, Liu Hongyan, Huang Zhen, Mapo and other shareholders to their holdings of the company's shares transferred to the new shareholder Sumin, Yiu Dingbong, of which Liu Hongyan, Huang Zhen, Mapo respectively 3 million yuan, 1.5 million yuan 1.5 million yuan of the price of its companies holding 1%, 0.5%, 0.5% of the equity transfer to Yiu Dingbong, Chen Lijia will be held by its company 0.5% of the shares of 1.5 million yuan to the price of the transfer to Sumin.　　The share transfer price is valued at 300 million yuan and determined by consultation.　　Watson Bio sponsor Ping An securities stressed that the directors, supervisors, senior managers, other core personnel of the company issuer and the main handling personnel of the intermediary agencies of the issue have also explained separately that they do not have any relationship with Yiu Dingbong, Sumin, or have not passed Sumin, Yiu Dingbong hold Watson's biological shares or similar arrangements. Data show that Yiu Dingbong from August 1983 to October 2006 in Yunnan Radio and television University as staff, in the November 2006 to date in China medicine Peng Overseas Pharmaceutical Co., Ltd. engaged in sales work.　　Sumin has been a graduate student at Kunming University of Technology from September 2005 to July 2007 and has been a full-time teacher in Tianjin University of Technology, Kunming, since January 2008.　　Under the fund's net, the sky-high price of Watson's biology is linked to a network of institutional investors represented by the fund. Watson's Bio-issue listing announced that a total of 81 inquiry Object Agent 161 stock placement objects submitted a preliminary inquiry declaration information.　　Among them, the initial inquiry quotation is not lower than the price of all valid quotations corresponding to the cumulative number of the proposed purchase amount of 231.3 million shares, the excess subscription is 46.26 times times. The final results show that Watson's bio-final issuer pricing is higher than the weighted average and median of all stock placement objects.　　Previously, the weighted average of all stock placements was 92.47 yuan and the median was 92.00 yuan.　　Among them, the fund company shares placing objects 89, the purchase quantity occupies the ratio up to 54.05%, occupies the dominant position, its declaration interval is located 73.00 yuan/shares-110.00 yuan/shares.　　This reporter found that the Watson biology of the lowest quotations and the highest quotations are submitted by brokers, respectively, 20.00 yuan/Unit and 130 yuan/share, corresponding to the 2009 after the diluted earnings ratio of 183.1 times times and 28.17 times times respectively. It is worth mentioning that the gem and the Board of similar listingWatson's biology has a higher-than-earnings ratio. Relevant data indicate that the closing price as at October 27, 2010, including the Gem, Huaren biology, bio, bio, the pharmaceutical industry, Canchi pharmaceutical industry and the Red Sun pharmaceutical industry, including six gem companies 2009 static P/E ratio 59.86 times times, 4 main business similar to the company Temple of Heaven Biology, Hualan Biology, da an gene, Changchun high-tech average static P/E ratio is 72.97 times times.　　Watson, by contrast, has a 133.8 times-fold earnings ratio of 123.52% and 83.36%, respectively.　　And Ping An securities that the price is higher than the average value of the company, but given the growth of the company, give a certain premium is appropriate.　　This reporter learned that Watson's life of the sky-high distribution also greatly exceeded the accident of brokerage fellows. Li Shuhua, chief analyst of Oriental Securities and medicine industry, said that according to its earnings forecasts, the company's 2010, 2011 and 2012 earnings per share of 1.54 yuan, 2.68 yuan, 4.03 yuan.　　With a 2010-year forecast P/E ratio of 45-50 times, the corresponding reasonable price range should be 69.3-77.0 yuan. China Merchants Securities researcher Shan said that in June 2009, the company will be engaged in the sale of vaccine products Agent Worsen 100% shares transferred to the independent third party, the current sales of vaccine products only Hib and freeze-dried A, C group meningococcal polysaccharide conjugate vaccine 2, all belong to bacterial vaccine. In addition, HIB sales revenue accounted for 100%, 100%, 82.76%, 81.23%, respectively, in the production of vaccine products. If the existing vaccine product sales have unpredictable fluctuations or new products can not be successfully listed, the company's operating performance will have a greater impact.